Haemonetics (HAE) EBITDA (2009 - 2026)

Haemonetics' EBITDA history runs 18 years deep, the most recent figure standing at -$23.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 132.28% year-over-year to -$23.0 million; the TTM figure through Mar 2026 stood at $156.7 million (down 2.75% YoY), while the FY2026 annual figure was $156.7 million, down 29.34% from the prior year.
• EBITDA was -$23.0 million for Q1 2026 at Haemonetics, down from $67.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $71.3 million in Q1 2025 to a low of -$23.0 million in Q1 2026.
• Historically, EBITDA has averaged $33.6 million across 5 years, with a median of $33.3 million in 2023.
• The sharpest annual moves came in 2022 and 2026: EBITDA surged 427.28% in 2022, then slumped 132.28% in 2026.
• A 5-year view of EBITDA shows it stood at $37.4 million in 2022, then rose by 5.79% to $39.6 million in 2023, then sank by 58.15% to $16.6 million in 2024, then soared by 307.05% to $67.4 million in 2025, then plunged by 134.16% to -$23.0 million in 2026.
• The last three EBITDA figures came in at -$23.0 million (Q1 2026), $67.4 million (Q4 2025), and $58.5 million (Q3 2025), per Business Quant data.